Canaccord analyst Whitney Ijem initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $74 price target The company’s last 12-18 months has been “impressive.” Canaccord thinks news flow this year, starting soon with BEAM-302 data by the end of Q1, will drive share upside. Beam continues its transformation “from a cool platform (said in a whisper) story to late-stage clinical co with compelling data in large orphan markets,” the analyst tells investors in a research note. Canaccord expects the company to maintain its execution momentum in 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics initiated with a Buy at Canaccord
- Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
- Beam Therapeutics Secures Standby License for Key Patents
- Beam Therapeutics announces upcoming board member resignation
- Beam Therapeutics participates in a conference call with William Blair